You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 16 Next »

  1. The Trial Sets (TX) domain provides the list of distinct sets of subjects or sources of information (REFIDs) having different experimental factors, treatment factors, inherent characteristics, or distinct applicant designations as specified in the trial design.
  2. Each trial set must be identified by a SETCD that is unique within the trial. The SETCD is assigned by the applicant.
  3. Each trial set should have a SPGRPCD in TXPARMCD with corresponding parameter value under TXVAL. In many cases, more than 1 trial set may be assigned the same group number in the protocol. The inclusion of this parameter facilitates the ability to reference information in the protocol provided and as part of the submission.
  4. The SPGRPCD parameter value may be used for sorting when viewing the data. applicants should consider utilizing values that will sort alphabetically in an order intended by the applicant.
  5. The TXPARMCD and TXPARM list may be extended by the applicant as needed to provide the information on experimental factors that differentiate trial sets.
  6. In general, each set should have a distinct combination of TXPARMCD, TXPARM, and TXVAL whenever possible. If 2 trial sets (identified by distinct SETCD values) have the same set of TXPARMCD, TXPARM, and TXVAL entries, the SET variable must contain information that distinguishes the sets from each other.
  7. Some --PARMCD values are available to both the Trial Summary (TS) and TX domains in order to allow for further description of how those values apply to individual trial sets. However, if the attributes (TXPARMCD) are identical across trial set, including them in TS is sufficient.  TOBA-73 - Getting issue details... STATUS
  8. In vivo studies:
    1. There should be no planned parameters of interest that could further subdivide a trial set. Each trial set should be assigned to a single group. Each trial set in an in vivo study should be assigned to a single trial arm.
    2. Trial sets should be designed so that each individual subject shall participate in 1 and only 1 trial set.
    3. The ARMCD parameter should be used to associate each trial set with a trial arm as defined in the Trial Arms (TA) table. Each trial set should only have 1 ARMCD parameter, but more than 1 trial set may have the same value of the ARMCD parameter.
    4. The applicant may choose to define subjects of different sexes as distinct trial sets if this is appropriate based upon the trial design. Alternatively, if all other parameters are the same, sets can be defined to contain both sexes under the assumption that it is common practice to analyze male and female subjects separately.
  9. In vitro studies:
    1. Trial sets can be further subdivided into additional trial sets. This parent-child relationship is defined in the RELREF dataset. TOBA-473 - Getting issue details... STATUS
    2. A trial set inherits all the parameter codes of all it's ancestors' trial sets. TOBA-468 - Getting issue details... STATUS It is appropriate to specify a parameter code value at a parent level if it's value is the same for all the trial sets of its descendants. Conversely, a parameter code must be specified at a parent trial set only if it's value is the same for all of the trial sets in it's descendants. 
    3. Each source of information is directly associated with only one trial set TOBA-478 - Getting issue details... STATUS which in turn may be a subset of other trial sets.
    4. Trial arms do not typically apply to in vitro studies.
    5. A trial can include more than one genetic toxicology assay (indicated by values for GNTXAID).  TXPARMCD and TXVAL values will likely be different for different values of GNTXAID.  TOBA-496 - Getting issue details... STATUS TOBA-465 - Getting issue details... STATUS TOBA-464 - Getting issue details... STATUS
  • No labels